The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma
Open accessAbstract
Pancreatic ductal adenocarcinoma (PDA) is a lethal malignancy with limited treatment options. Although metabolic reprogramming is a hallmark of many cancers, including PDA, previous attempts to target metabolic changes therapeutically have been stymied by drug toxicity and tumour cell plasticity. Here, we show that PDA cells engage an eIF4F-dependent translation program that supports redox and central carbon metabolism. Inhibition of the eIF4F subunit, eIF4A, using the synthetic rocaglate CR-1-31-B (CR-31) reduced the viability of PDA organoids relative to their normal counterparts. In vivo, CR-31 suppresses tumour growth and extends survival of genetically-engineered murine models of PDA. Surprisingly, inhibition of eIF4A also induces glutamine reductive carboxylation. As a consequence, combined targeting of eIF4A and glutaminase activity more effectively inhibits PDA cell growth both in vitro and in vivo. Overall, our work demonstrates the importance of eIF4A in translational control of pancreatic tumour metabolism and as a therapeutic target against PDA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A synthetic eIF4A inhibitor, CR-1-31B, has shown potent activity against many cancer cell lines and promising efficacy in several mouse models (15, 17, 20, 21, 32, 33).”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“eIF4A inhibitors, which target both isoforms, suppress translation of key oncogenes and have demonstrated antitumor activity in a variety of cancers (15, 17, 19–22).”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Our results build on studies in mouse models of other cancers, including lymphoma, leukemia, breast, prostate, and pancreatic cancer, supporting the tolerability and efficacy of eIF4A inhibitors (15, 17, 20, 21, 38).”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
O'Leary, N. A., Wright, M. W., Brister, J. R., Ciufo, S., Haddad, D., McVeigh, R., Rajput, B., Robbertse, B., Smith-White, B., Ako-Adjei, D., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1189 · Cited by 6,357
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets
Sonenberg, N., & Hinnebusch, A. G. (2009) · Cell · doi:10.1016/j.cell.2009.01.042 · Cited by 3,304
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Organoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150
Self-citationThe Nrf2 regulatory network provides an interface between redox and intermediary metabolism
Hayes, J. D., & Dinkova-Kostova, A. T. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.02.002 · Cited by 2,141
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
New approach for understanding genome variations in KEGG
Kanehisa, M., Sato, Y., Furumichi, M., Morishima, K., & Tanabe, M. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky962 · Cited by 1,845
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Mendoza, M. C., Er, E. E., & Blenis, J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.03.006 · Cited by 1,817
Cited by
Alternative approaches to target Myc for cancer treatment
Wang, C., Zhang, J., Yin, J., Gan, Y., Xu, S., Gu, Y., & Huang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00500-y · Cited by 238
NRF2: KEAPing Tumors Protected
Pillai, R., Hayashi, M., Zavitsanou, A.-M., & Papagiannakopoulos, T. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0922 · Cited by 184
Protein synthesis control in cancer: selectivity and therapeutic targeting
Kovalski, J. R., Kuzuoğlu‐Öztürk, D., & Ruggero, D. (2022) · The EMBO Journal · doi:10.15252/embj.2021109823 · Cited by 130
Glutaminases regulate glutathione and oxidative stress in cancer
Matés, J. M., Campos-Sandoval, J. A., de los Santos-Jiménez, J., & Márquez, J. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02838-8 · Cited by 91
Dual targeting of DDX3 and eIF4A by the translation inhibitor rocaglamide A
Chen, M., Asanuma, M., Takahashi, M., Shichino, Y., Mito, M., Fujiwara, K., Saito, H., Floor, S. N., Ingolia, N. T., Sodeoka, M., et al. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.11.008 · Cited by 82
Metadata
- Authors
- Chan, K., Robert, F., Oertlin, C., Kapeller-Libermann, D., Avizonis, D., Gutierrez, J., Handly-Santana, A., Doubrovin, M., Park, J., Schoepfer, C., Da Silva, B., Yao, M., Gorton, F., Shi, J., Thomas, C. J., Brown, L. E., Porco, J. A., Pollak, M., Larsson, O., Pelletier, J., & Chio, I. I. C.
- Affiliations
- Columbia University Irving Medical Center (US)
- McGill University (CA)
- Karolinska Institutet (SE)
- Cold Spring Harbor Laboratory (US)
- University of Pennsylvania (US)
- National Cancer Institute (US)
- Boston University (US)
- Corresponding author
- Larsson, Ola
- Pelletier, Jerry
- Chio, Iok In Christine
- ORCID
- Venue
- Nature Communications
- Published
- 2019-11-13
- Volume
- 10
- Issue
- 1
- Pages
- 5151-5151
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC6853918
- OpenAlex
- W2988312256
- Cited by
- 106
- References
- 70
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 20 · 2023: 20 · 2022: 16 · 2021: 24 · 2020: 9
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- OpenBU (Boston University) (submittedVersion)
- Funders
- Pancreatic Cancer Action Network (PANCAN 18-35-CHIO)
- V Foundation for Cancer Research (VFND V2018-017)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- eIF4A, pancreatic ductal adenocarcinoma, eIF4F, translational regulation, metabolic reprogramming, rocaglates, glutaminase, cancer metabolism, oncogenic translation, tumor organoids, anticancer drug targets
- MeSH terms
- Animals, Glutathione, Humans, Mice, Inbred C57BL, Oxidation-Reduction, Pancreatic Neoplasms, Protein Biosynthesis, Carcinoma, Pancreatic Ductal, Eukaryotic Initiation Factor-4A, Cell Line, Tumor, Molecular Targeted Therapy, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma. https://app.cochat.ai/papers/10.1038/s41467-019-13086-5
- The paper
- Chan, K., Robert, F., Oertlin, C., Kapeller-Libermann, D., Avizonis, D., Gutierrez, J., Handly-Santana, A., Doubrovin, M., Park, J., Schoepfer, C., Da Silva, B., Yao, M., Gorton, F., Shi, J., Thomas, C. J., Brown, L. E., Porco, J. A., Pollak, M., Larsson, O., . . . Chio, I. I. C. (2019). eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma. Nature Communications. https://doi.org/10.1038/s41467-019-13086-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.